3-羟基-4-溴苯甲酸 | 14348-38-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-羟基-4-溴苯甲酸
• 中文别名: 4-溴-3-羟基苯甲酸
• 英文名称: 4-bromo-3-hydroxybenzoic acid
• CAS: 14348-38-0
• 化学式: C₇H₅BrO₃
• mdl: MFCD08056371
• 分子量: 217.019
• InChiKey: PAJSESFUWIYFNF-UHFFFAOYSA-N

物化性质

• 熔点：
  225-227
• 沸点：
  338.6±32.0 °C(Predicted)
• 密度：
  1.861±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918290000
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-3-hydroxybenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-hydroxybenzoic acid
CAS number: 14348-38-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrO3
Molecular weight: 217.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

4-溴-3-羟基苯甲酸是一种Brocresine的代谢产物，也是一种组氨酸脱羧酶（HDC）抑制剂。它对大鼠胎儿和大鼠胃中HDC的IC50均为1 mM。此外，该化合物还可以在体外抑制猪肾脏和大鼠胃黏膜中的芳香族L-氨基酸脱羧酶（aromatic-L-amino acid decarboxylase），两种酶的IC50同样为1 mM。

体外研究

• IC50: 1 mM (大鼠胎儿组氨酸脱羧酶 (HDC)), 1 mM (大鼠胃组氨酸脱羧酶), 1 mM (猪肾脏芳香族L-氨基酸脱羧酶), 1 mM (大鼠胃黏膜芳香族L-氨基酸脱羧酶)

反应信息

• 作为反应物：
  描述：

  3-羟基-4-溴苯甲酸 在 sodium hydroxide 作用下， 生成 原儿茶酸
  参考文献：
  名称：

  DE71260

  摘要：

  公开号：
• 作为产物：
  描述：

  间羟基苯甲酸 在 溴 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以40%的产率得到3-羟基-4-溴苯甲酸
  参考文献：
  名称：

  通过烯类的卤化芳香化合成基于苯并呋喃的曲霉B。

  摘要：

  报道了通过烯酮的氧化卤代芳构化合成基于苯并呋喃的天然产物的新型“非芳族库”合成策略。该方法已成功应用于天然产物曲霉B的第一次全合成中。与单独执行的“芳族库”合成相比，“非芳族库”协议具有同等效率，但提供了更高的模块化程度。

  DOI：

  10.1021/acs.orglett.0c01259
• 作为试剂：
  描述：

  间羟基苯甲酸 、 溴 在 3-羟基-4-溴苯甲酸 作用下， 以 溶剂黄146 为溶剂， 以to give 4-bromo-3-hydroxybenzoic acid as a colourless crystalline solid (3.43 g, 12%)的产率得到3-羟基-4-溴苯甲酸
  参考文献：
  名称：

  Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity

  摘要：

  本发明涉及公式III或公式IV的类固醇硫酸酯酶和/或芳香化酶抑制剂，其中A从H，OH，卤素和烃基中选择；D，E和F各自独立地是可选的连接基团；P，Q和R各自独立地是环系统，其中R4和R5分别独立地选择自H，烷基，环烷基，烯基，酰基和芳基，或其组合，或者一起表示为烷基，其中每个烷基或环烷基或烯基或可选地含有一个或多个杂原子或基团，可用于医学。

  公开号：

  US08148415B2

文献信息

• Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
  申请人：Failli A. Amedeo

  公开号：US20060199806A1

  公开（公告）日：2006-09-07

  This invention provides pyrrolobenzodiazepine arylcarboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists, as well as pharmaceutical compositions and methods of treatment

  这项发明提供了从式（1）中选择的吡咯苯并二氮杂环芳基甲酰胺，其作为促卵泡生成激素受体拮抗剂，以及药物组合物和治疗方法。
• Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
  申请人：Failli A. Amedeo

  公开号：US20060287522A1

  公开（公告）日：2006-12-21

  This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

  这项发明提供了从式（1）中选择的吡咯苯并二氮杂吡咯烷吡啶羧酰胺，其作为卵泡刺激素受体拮抗剂。该发明还提供了利用式（1）和（2）化合物的药物组合物和治疗方法。
• [EN] DIHYDROQUINOLIZINONES AS ANTIVIRALS<br/>[FR] DIHYDROQUINOLIZINONES À UTILISER EN TANT QU'ANTIVIRAUX
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018154466A1

  公开（公告）日：2018-08-30

  Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds. Formula (I):

  化合物，具体来说是乙型肝炎病毒和/或丙型肝炎病毒抑制剂，更具体地说是抑制受试者体内HBe抗原和HBs抗原的化合物，用于治疗病毒感染，并且涉及制备和使用这类化合物的方法。化学式（I）:
• [EN] PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)<br/>[FR] DERIVES DE PYRROLIDINE-2-CARBONITRILE ET LEUR UTILISATION COMME INHIBITEURS DE LA DIPEPTIDYLE PEPTIDASE-IV (DPP-IV)
  申请人：ABBOTT LAB

  公开号：WO2005023762A1

  公开（公告）日：2005-03-17

  The present invention relates to compounds of formula (I), (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, b-cell failure, obesity, satiety disorders, atherosclerosis, and various immunomodulatory diseases.

  本发明涉及式(I)、(I)的化合物，其抑制二肽基肽酶IV（DPP-IV），并且对于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖、X综合征、高胰岛素血症、β细胞功能衰竭、肥胖、饱腹障碍、动脉粥样硬化和各种免疫调节性疾病有用。
• New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa
  申请人：——

  公开号：US20020198195A1

  公开（公告）日：2002-12-26

  The present invention relates to compounds comprising the following formula: R 0 —Q—X—Q′—W—U—V—G—M  (I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

  本发明涉及包含以下公式的化合物： R 0 —Q—X—Q′—W—U—V—G—M  (I) 这些化合物作为药物活性化合物是有用的。它们展现出抗血栓作用，并适用于例如治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。这些化合物是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆性抑制剂，通常可用于治疗、预防或治愈存在因子Xa和/或因子VIIa不期望活性的情况，或旨在抑制因子Xa和/或因子VIIa的情况。本发明还涉及制备这些化合物的方法、它们的使用方法（例如，作为药品中的活性成分）以及包含它们的药物制剂。